Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 356,900 shares, a decrease of 18.6% from the December 15th total of 438,500 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average daily volume of 100,900 shares, the days-to-cover ratio is presently 3.5 days.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 33.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $256,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a research note on Sunday, January 12th. They set a “hold” rating on the stock.

Aspira Women’s Health Stock Down 3.1 %

NASDAQ AWH traded down $0.02 on Friday, reaching $0.50. 65,362 shares of the stock traded hands, compared to its average volume of 83,260. Aspira Women’s Health has a 12 month low of $0.38 and a 12 month high of $5.65. The firm’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.93. The company has a market cap of $8.34 million, a price-to-earnings ratio of -0.42 and a beta of 1.42.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.